In the published article, there was an error in the Funding statement. The funder “Duchenne UK” was erroneously excluded. The correct Funding statement appears below.
“The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors would like to thank the Parent Project Muscular Dystrophy (PPMD) and Duchenne UK for funding this work.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
AAV9, mdx , Duchenne muscular dystrophy, DMD, gene therapy, immune response, TLR, complement
Citation
Spathis R, Kuriplach DR, Narvesen S, Eybs M, Huang K, Torres S, King M, Bagley E, Elustondo P, Lawlor MW, Nagaraju K and Morales M (2025) Corrigendum: Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis. Front. Immunol. 16:1593193. doi: 10.3389/fimmu.2025.1593193
Received
13 March 2025
Accepted
14 March 2025
Published
21 March 2025
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
16 - 2025
Updates
Copyright
© 2025 Spathis, Kuriplach, Narvesen, Eybs, Huang, Torres, King, Bagley, Elustondo, Lawlor, Nagaraju and Morales.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Melissa Morales, mmorales@binghamton.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.